Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company’s lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago. At the General Poster Session on June 6 from 8 AM to 12 PM, preliminary results from the ongoing Phase 1 open-label, multi-center dose escalation trial evaluating the safety and tolerability of multiple doses of Sym004 will be provided. The poster is entitled “Phase I Trial Of The First-In-Class EGFR mAb Mixture, Sym004, In Patients With Refractory Advanced Solid Tumors” by Dr. Rodrigo Dienstmann of the Vall d’Hebron University Hospital, Barcelona, Spain.
About Sym004
Sym004 is a novel anti-EGFR monoclonal antibody (mAb) mixture, comprised of two mAbs that targets two distinct and non-overlapping epitopes in domain III of EGFR. The two mAbs rapidly eliminate EGFR and lead to cancer cell death (Pedersen et al (2010) Cancer Research).
Source:
Symphogen
